December 26, 2018 - The Court of Appeals affirmed the court's decision. The case as dismissed.

April 12, 2018 - A notice of appeal was filed.

March 13, 2018 - The court dismissed the case.

May 1, 2017 - A motion to dismiss the amended complaint was filed.

March 17, 2017 - An amended complaint was filed.

November 9, 2016 (Shareholders Foundation) - An investor in shares of ProNAi Therapeutics Inc (NASDAQ:DNAI) filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by ProNAi Therapeutics Inc in connection with certain allegedly false and misleading statements made between July 15, 2015 and June 6, 2016.

According to the complaint the plaintiff alleges on behalf of purchasers of ProNAi Therapeutics Inc (NASDAQ:DNAI) common shares between July 15, 2015 and June 6, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between July 15, 2015 and June 6, 2016 ProNAi Therapeutics Inc made allegedly materially false and misleading statements about the potential and efficacy of its drug product candidate PNT2258 in the company’s public filings, which caused ProNAi’s stock price to be artificially inflated between July 15, 2015 and June 6, 2016, thus harming investors.

On June 6, 2016, ProNAi Therapeutics Inc (NASDAQ:DNAI announced interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). ProNAi Therapeutics Inc’s President and CEO Nick Glover said, “Although [PNT2258] observed modest efficacy …in [the] interim analysis of Wolverine,” the Company has “decided to suspend the development of PNT2258” because the results were not “robust enough to justify continued development of the drug in DLBCL.”

Shares of ProNAi Therapeutics Inc (NASDAQ:DNAI) declined from $6.70 per share on June 2, 2016, to $1.98 per share on June 10, 2016.